Immuneering Corporation

NASDAQ : IMRX

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Information

Website
https://immuneering.com
Sector
Healthcare
Industry
Biotechnology
Type
Common Stock
Country
United States

Price

USD 2.66

Symbol

IMRX

Type

Common Stock

Previous Close

 :

2.61

52 Week Range

 :

1.00 - 9.00

Volume

 :

1,553,100.00

Average Volume

 :

15,178,430.00

High

 :

2.81

Low

 :

2.45

Change

 :

0.05

Percent change (%)

 :

1.92

Stakeville

A Free-to-Play Trading Game. Sharpen your skills, trade stocks, and have fun!

Play Now
Getting Started
Get Your Free Account For Educational Purpose Knowledgebase
Legal
Cookie Policy Privacy Policy Terms & Conditions
Customer Service
Help Desk Support Stakeville Newsletter
Stay Connected
Contact Us Official Blog About Us
Disclaimer: Stakeville is a simulation trading game. All trades and stock prices are fictional and do not reflect real-world markets. This game is for entertainment purposes only and does not involve real financial transactions. Read more...